RECRUITING
I'm interested ...!!
Immune Function and the Progression to T1D
To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.
Conditions:
🦠 Type 1 Diabetes
🗓️ Study Start (Actual) 1 January 2005
🗓️ Primary Completion (Estimated) 1 January 2085
✅ Study Completion (Estimated) 1 January 2085
👥 Enrollment (Estimated) 2800
🔬 Study Type OBSERVATIONAL
📊 Phase N/A
Locations:
📍 Gainesville, Florida, United States
📍 Columbus, Ohio, United States
📍 Houston, Texas, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

      Exclusion Criteria:

      • -
    Ages Eligible for Study: 0 Years to 100 Years (CHILD, ADULT, OLDER_ADULT)
    Sexes Eligible for Study: ALL
    Accepts Healthy Volunteers: Yes

    🗓️ Study Record Dates

    These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

    Study Registration Dates

    • First Submitted 22 May 2023
    • First Submitted that Met QC Criteria 1 June 2023
    • First Posted 12 June 2023

    Study Record Updates

    • Last Update Submitted that Met QC Criteria 27 February 2024
    • Last Update Posted 28 February 2024
    • Last Verified June 2023
    I'm interested ...!!